Table 2.
Patients stratified by Sokal risk score and response to imatinib and nilotinib.
| Sokal Risk Imatinib (IRIS) |
Low Risk (%) |
Intermediate Risk (%) |
High Risk (%) |
|||
|---|---|---|---|---|---|---|
| CCyR (p<0.001) | 89 | 82 | 69 | |||
| Disease progression at 60 months | 3 | 8 | 17 | |||
| No disease progression in patients with CCyR | 99 | 95 | 95 | |||
| Nilotinib vs. imatinib (ENESTnd) | I | N | I | N | I | N |
| Best cumulative MMR by 3 years* | 62.5 | 76.7 | 54.5 | 75.2 | 38.5 | 66.7 |
*
After the 2-year visit, cytogenetic assessments were not required for all patients, hence no CCyR rates are available.
Abbreviations: CCyR, complete cytogeneric remission; I, imatinib; IRIS, International Randomized study of Interferon and STI571; N, nilotinib.